Skip to main content
Premium Trial:

Request an Annual Quote

Lustgarten Forms Consortium for Pancreatic Cancer Biomarker Research

NEW YORK (GenomeWeb News) – The Lustgarten Foundation for Pancreatic Cancer said today it plans to launch a $1.25 million project to develop antibodies for biomarker targets for pancreatic cancer, the Foundation said today.
 
The Pancreatic Cancer Biomarker Development Project is a consortium of four research organizations including Canary Foundation, Dana-Farber Cancer Institute, University of California at San Francisco and Van Andel Research Institute.
 
“Ultimately, it is our hope that this project will lead to the development of new diagnostic methods, and that screening for pancreatic cancer can someday be as simple as receiving a blood test in your doctor's office,” said Lustgarten Executive Director Kerri Kaplan.
 
The Lustgarten Foundation also said it launched an initiative to sequence and analyze the genetic code of pancreatic cancer tumors.
 
The Foundation noted that pancreatic cancer is the fourth leading cause of cancer deaths in the US.

The Scan

Tennessee's COVID-19 Sequencing

The Tennessean reports that a state lab there can now run its own genome sequencing analyses of SARS-CoV-2 samples.

Sanction Violation Charges

A former professor has been charged with exporting genetic sequencing equipment to Iran in violation of US sanctions, the Miami Herald reports.

Prenetics to Go Public Through SPAC

Prenetics, a Hong Kong-based genomic and diagnostic company, is going public through a SPAC merger, according to 360Dx.

Nature Papers Examine Genomes of Centenarians, Transcription-Coupled DNA Repair

In Nature this week: analysis of centenarian genomes uncovers longevity-linked variants, and more.